The right-back for Manchester United and Portugal national team has committed over €1 million to the personalised nutrition company, which specialises in creating bespoke nutritional supplements based on blood biomarker analysis. This significant investment comes after Dalot’s four-year journey as a dedicated Bioniq customer, during which he has integrated the company’s personalised formulations into his professional performance regimen.
Founded in 2019, Bioniq has established itself as a frontrunner in the personalised nutrition sector, with its valuation now reaching $82 million. The company originally developed its science-backed approach to improve physical and cognitive function for Olympic athletes, but has since expanded to serve customers across 70 countries worldwide.
A personal connection to performance nutrition
Dalot’s investment stems from his firsthand experience with the product. “When it comes to high-level performance, my biggest focus has always been finding that extra 1% – the key to setting myself apart from the rest,” the footballer explained. Having used Bioniq’s products since 2022, he described the supplements as “a game-changer” that delivered measurable results.
The Portuguese defender has been particularly drawn to the scientific, data-driven approach that underpins Bioniq’s offerings. His engagement with the brand extends beyond financial investment, as he actively collaborates with the product development team, offering insights from his perspective as an elite athlete.
With the launch of Bioniq’s hyper-personalised “Build Your Own” supplement line, Dalot has further refined his nutritional strategy, tailoring his nutrient intake to specific performance objectives. While he utilises the PRO formula to reduce inflammation, increase resilience and improve endurance, his additional customised supplements allow for controlled inflammatory responses that support muscle development.
Strategic growth in a booming market
Bioniq operates within the rapidly expanding supplements market, which was valued at $177.50 billion in 2023 and projects a compound annual growth rate of 9.1% between 2024 and 2030. The company’s user base has shown remarkable expansion, growing more than tenfold during 2024 alone.
Vadim Fedotov, Founder and CEO of Bioniq, praised Dalot’s approach to performance optimisation: “Diogo has an exceptional approach to performance optimisation and recovery, constantly seeking the most effective and scientifically backed methods to enhance his physical and cognitive capabilities.”
The CEO further emphasised the alignment between Dalot’s performance philosophy and the company’s vision, noting that both recognise “the future of health lies in precision, personalisation, and efficacy.”
Building on celebrity investment momentum
Dalot’s financial commitment follows the high-profile investment made by his national teammate Cristiano Ronaldo earlier in 2024. These celebrity endorsements complement a successful Series B funding round that raised $15 million, led by Principal Investors HV Capital and Unbound.
The nutritional science company has built strong partnerships with prominent health and sports organisations, including Lanserhof and UFC. Its appeal extends across the professional sports spectrum, attracting Soccer World Cup Champions, NBA All-Stars and Iron Man winners.
A key factor in these partnerships has been Bioniq’s ability to provide quantifiable before-and-after analyses of users’ nutritional needs and optimisation progress. This data-driven approach offers athletes concrete evidence of improvement, moving beyond the subjective assessments common in the supplement industry.
